INKEF Capital
Venture Capital
Active
Amsterdam, Netherlands
85
24M
51
6.07
33
0.40
8
- Stages of investment
- Areas of investment
Summary
In 2010 was created INKEF Capital, which is appeared as VC. The leading representative office of defined VC is situated in the Amsterdam. The company was established in Europe in The Netherlands.
The overall number of key employees were 7.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the INKEF Capital, startups are often financed by Union Square Ventures, Life Sciences Partners, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Healthinnovations, Gilde Healthcare. In the next rounds fund is usually obtained by Keen Venture Partners, Union Square Ventures, Rabobank.
The top amount of exits for fund were in 2018. The real fund results show that this VC is 48 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this INKEF Capital performs on 15 percentage points less the average number of lead investments. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Health Care, Biopharma. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight NMD Pharma, Rainier Therapeutics, Shapeways.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
- Check size
- 500K — 15M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 85
- Lead investments
- 33
- Exits
- 8
- Rounds per year
- 6.07
- Follow on index
- 0.40
- Investments by industry
- Biotechnology (29)
- Health Care (23)
- Software (21)
- Medical (16)
- Medical Device (15) Show 74 more
- Investments by region
-
- Netherlands (45)
- United States (16)
- Germany (5)
- Denmark (3)
- Switzerland (4) Show 4 more
- Peak activity year
- 2020
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 111M
- Group Appearance index
- 0.84
- Avg. company exit year
- 6
- Avg. multiplicator
- 2.78
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Precirix | 16 Mar 2022 | Biotechnology | Early Stage Venture | 94M | Brussels-Capital, City of Brussels, Belgium |
| iOnctura | 20 Jun 2024 | Biotechnology, Health Care, Medical Device | Early Stage Venture | 94M | Switzerland, Geneva, Geneva |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.